{"id":"cystine","rwe":[{"pmid":"41897515","year":"2026","title":"The Role of Ferroptosis in Diabetes Pathogenesis: Therapeutic Implications of Hydrogen Sulfide and Its Reactive Metabolites.","finding":"","journal":"Antioxidants (Basel, Switzerland)","studyType":"Clinical Study"},{"pmid":"41894394","year":"2026","title":"Methionine metabolism is linked with phospholipid and glutamine metabolism to drive ferroptosis.","finding":"","journal":"Cell reports","studyType":"Clinical Study"},{"pmid":"41892951","year":"2026","title":"Crude Venom from Sea Anemone Macrodactyla doreensis Suppresses Glioblastoma via the p53 Pathway.","finding":"","journal":"Marine drugs","studyType":"Clinical Study"},{"pmid":"41889857","year":"2026","title":"Discovery of metabolites produced by reactions between central carbon metabolites and cysteine that mark inflammatory macrophages.","finding":"","journal":"bioRxiv : the preprint server for biology","studyType":"Clinical Study"},{"pmid":"41879427","year":"2026","title":"Dimethyl fumarate combined with cisplatin at subcytotoxic doses sensitizes cervical cancer toward ferroptosis and apoptosis through GSH restriction and p53 (re)activation.","finding":"","journal":"Molecular oncology","studyType":"Clinical Study"}],"_fda":{"id":"2b538be3-baaa-3c2b-e063-6294a90a1489","set_id":"a6a13048-b1b4-4a46-acad-d379d4e4b6fb","openfda":{"nui":["N0000193618","M0001797"],"unii":["94ZLA3W45F","PQ6CK8PD0R","M2776SWB29","UGE0WQC19W","8XEJ88V2T8","48TCX9A1VT","VB06AV5US8","68Y4CF58BV","H6241UJ22B","92AMN5J79Y","X66NSO3N35","J41CSQ7QDS"],"route":["SUBLINGUAL"],"spl_id":["2b538be3-baaa-3c2b-e063-6294a90a1489"],"brand_name":["N-17"],"spl_set_id":["a6a13048-b1b4-4a46-acad-d379d4e4b6fb"],"package_ndc":["58264-0215-1"],"product_ndc":["58264-0215"],"generic_name":["ZINC, SELENIUM, BOS TAURUS THYMUS, SUS SCROFA SPLEEN, BOS TAURUS LYMPH, BOS TAURUS ADRENAL GLAND, ARGININE, CYSTINE, ECHINACEA ANGUSTIFOLIA, THIAMINE, PYRIDOXINE HYDROCHLORIDE, AND ASCORBIC ACID"],"product_type":["HUMAN OTC DRUG"],"pharm_class_cs":["Ascorbic Acid [CS]"],"substance_name":["ARGININE","ASCORBIC ACID","BOS TAURUS ADRENAL GLAND","BOS TAURUS LYMPH","BOS TAURUS THYMUS","CYSTINE","ECHINACEA ANGUSTIFOLIA","PYRIDOXINE HYDROCHLORIDE","SELENIUM","SUS SCROFA SPLEEN","THIAMINE","ZINC"],"pharm_class_epc":["Vitamin C [EPC]"],"manufacturer_name":["DNA Labs, Inc."],"is_original_packager":[true]},"purpose":["Support for immune deficiency."],"version":"3","warnings":["Warnings Use only if cap seal is unbroken. As with drugs if you are pregnant or nursing a baby seek professional advice before using this product. Keep this and all medication out of the reach of children. To be used according to standard homeopathic indications."],"effective_time":"20250109","active_ingredient":["INGREDIENTS Zincum metallicum 6x, Selenium metallicum 6x, Thymus 6/12/30/60/200x, Spleen 6/12/30/60/200x, Lymph 6/12/30/60/200x, Adrenal 6/12/30/60/200x, L-Arginine 4x, L-Cystine 4x, Echinacea angustifolia 6x, Vitamin B1 3x, B6 3x, Vitamin C 3x, 20% alcohol in purified water."],"inactive_ingredient":["INGREDIENTS Zincum metallicum 6x, Selenium metallicum 6x, Thymus 6/12/30/60/200x, Spleen 6/12/30/60/200x, Lymph 6/12/30/60/200x, Adrenal 6/12/30/60/200x, L-Arginine 4x, L-Cystine 4x, Echinacea angustifolia 6x, Vitamin B1 3x, B6 3x, Vitamin C 3x, 20% alcohol in purified water."],"storage_and_handling":["SHAKE WELL"],"indications_and_usage":["INDICATIONS Support for immune deficiency."],"spl_unclassified_section":["NDC 58264-0215-1"],"dosage_and_administration":["SUGGESTED DOSAGE One dropper under tongue two times daily. Acute symptoms ½ dropper under tongue every 30 minutes for two hours."],"spl_product_data_elements":["N-17 Zinc, Selenium, Bos taurus thymus, Sus Scrofa Spleen, Bos taurus lymph, Bos taurus adrenal gland, Arginine, Cystine, Echinacea angustifolia, Thiamine, Pyridoxine hydrochloride, and Ascorbic acid ALCOHOL WATER ZINC ZINC SELENIUM SELENIUM BOS TAURUS THYMUS BOS TAURUS THYMUS SUS SCROFA SPLEEN SUS SCROFA SPLEEN BOS TAURUS LYMPH BOS TAURUS LYMPH BOS TAURUS ADRENAL GLAND BOS TAURUS ADRENAL GLAND ARGININE ARGININE CYSTINE CYSTINE ECHINACEA ANGUSTIFOLIA ECHINACEA ANGUSTIFOLIA THIAMINE THIAMINE ION PYRIDOXINE HYDROCHLORIDE PYRIDOXINE ASCORBIC ACID ASCORBIC ACID"],"pregnancy_or_breast_feeding":["As with drugs if you are pregnant or nursing a baby seek professional advice before using this product."],"keep_out_of_reach_of_children":["Keep this and all medication out of the reach of children."],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL - 1 FL. OZ. Bottle Label DYNAMIC NUTRITIONAL ASSOCIATES, INC. N-17 IMMUTEC DROPS HOMEOPATHIC ENDOCRINE 1 FL. OZ. Principal Display Panel - 1 FL. OZ. Bottle Label"]},"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"TRANSPLANT REJECTION","source":"FDA FAERS","actionTaken":"2 reports"},{"date":"","signal":"ABDOMINAL DISCOMFORT","source":"FDA FAERS","actionTaken":"1 reports"},{"date":"","signal":"ABDOMINAL PAIN","source":"FDA FAERS","actionTaken":"1 reports"},{"date":"","signal":"ANHEDONIA","source":"FDA FAERS","actionTaken":"1 reports"},{"date":"","signal":"AORTIC VALVE INCOMPETENCE","source":"FDA FAERS","actionTaken":"1 reports"},{"date":"","signal":"AORTIC VALVE SCLEROSIS","source":"FDA FAERS","actionTaken":"1 reports"},{"date":"","signal":"ASTHENIA","source":"FDA FAERS","actionTaken":"1 reports"},{"date":"","signal":"ATRIAL FIBRILLATION","source":"FDA FAERS","actionTaken":"1 reports"},{"date":"","signal":"CARDIAC ANEURYSM","source":"FDA FAERS","actionTaken":"1 reports"},{"date":"","signal":"CARDIAC MURMUR","source":"FDA FAERS","actionTaken":"1 reports"}]},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=CYSTINE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:35:33.801396+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Cystine","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T00:35:42.105015+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:35:40.591415+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CYSTINE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:35:41.058815+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:35:32.565630+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:35:32.565659+00:00"},"indications.approved":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:24:12.975036+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:35:32.565665+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T00:35:42.530513+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL590540/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:35:41.755851+00:00"}},"allNames":"l-cystine","offLabel":[],"synonyms":["cystine","L-cystine"],"timeline":[],"approvals":[],"brandName":"L-Cystine","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"Vitamin C [EPC]","explanation":"","oneSentence":"","technicalDetail":"L-Cystine is a dimer of L-cysteine, formed through the oxidation of two cysteine molecules. It plays a crucial role in the synthesis of glutathione, a powerful antioxidant that helps protect cells from oxidative stress."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Cystine","title":"Cystine","extract":"Cystine is the oxidized derivative of the amino acid cysteine and has the formula (SCH2CH(NH2)CO2H)2. It is a white solid that is poorly soluble in water. As a residue in proteins, cystine serves two functions: a site of redox reactions and a mechanical linkage that allows proteins to retain their three-dimensional structure.","wiki_history":"=== History ===\n \nCystine was discovered in 1810 by the English chemist William Hyde Wollaston, who called it \"cystic oxide\". In 1833, the Swedish chemist Jöns Jacob Berzelius named the amino acid \"cystine\". The Norwegian chemist Christian J. Thaulow determined, in 1838, the empirical formula of cystine. In 1884, the German chemist Eugen Baumann found that when cystine was treated with a reducing agent, cystine revealed itself to be a dimer of a monomer which he named \"cysteïne\". The chemical structure of cystine was determined by synthesis in 1903 by the German chemist Emil Erlenmeyer.\n\nThe history of cystine and cysteine is complicated by the dimer-monomer relationship of the two. The cysteine monomer was proposed as the actual unit by Embden in 1901.\n\nThe sulfur within the structure of cysteine and cystine has been subject of historical interest. In 1902, Osborne partially succeeded in analysing cystine content via lead compounds. An improved colorimetric method was developed in 1922 by Folin and Looney. An iodometric analysis method was developed by Okuda in 1925."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4130","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=CYSTINE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CYSTINE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Cystine","fields":["history","overview"],"source":"Wikipedia"}],"_enrichedAt":"2026-03-30T10:22:45.058475","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:35:43.845465+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[],"genericName":"cystine","indications":{"approved":[{"id":"cystine-immune-deficiency-support","name":"Immune Deficiency Support","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with immune deficiency","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with immune deficiency","diagnosticRequired":null,"brandNameForIndication":"L-Cystine"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT07348120","phase":"NA","title":"Efficacy and Safety of Millet Seed Extract in Telogen Effluvium Treatment","status":"COMPLETED","sponsor":"Kasr El Aini Hospital","startDate":"2025-05-01","conditions":["Telogen Effluvium"],"enrollment":60,"completionDate":"2026-03-01"},{"nctId":"NCT00359684","phase":"","title":"Use of Cysteamine in the Treatment of Cystinosis","status":"RECRUITING","sponsor":"National Human Genome Research Institute (NHGRI)","startDate":"1979-01-04","conditions":["Cystinosis"],"enrollment":330,"completionDate":""},{"nctId":"NCT06790342","phase":"PHASE3","title":"Optimizing Treatment of Co-occurring Smoking and Unhealthy Alcohol Use Among PWH in Nairobi, Kenya","status":"NOT_YET_RECRUITING","sponsor":"University of Chicago","startDate":"2026-06-01","conditions":["HIV","Tobacco Use","Alcohol Use Disorder"],"enrollment":300,"completionDate":"2030-02-01"},{"nctId":"NCT04818034","phase":"PHASE2","title":"The Effect of Sodium-glucose Cotransporter (SGLT) 2 Inhibitors on Cystine Stone Formation: A Preliminary Study","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2021-08-30","conditions":["Cystinuria"],"enrollment":10,"completionDate":"2022-04-28"},{"nctId":"NCT05400733","phase":"NA","title":"Prandial Metabolic Phenotype in Adults","status":"RECRUITING","sponsor":"Texas A&M University","startDate":"2022-06-24","conditions":["Protein Metabolism"],"enrollment":50,"completionDate":"2026-09"},{"nctId":"NCT04244630","phase":"PHASE2","title":"Mitochondrial Capacity Boost in ALS (MICABO-ALS) Trial","status":"RECRUITING","sponsor":"Dallas VA Medical Center","startDate":"2023-11-02","conditions":["Amyotrophic Lateral Sclerosis (ALS)"],"enrollment":60,"completionDate":"2025-12"},{"nctId":"NCT00588562","phase":"","title":"Rare Kidney Stone Consortium Patient Registry","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2003-07","conditions":["Primary Hyperoxaluria","Dent Disease","Cystinuria","APRT Deficiency"],"enrollment":730,"completionDate":"2028-06"},{"nctId":"NCT03337360","phase":"NA","title":"The Impact of a Nutritional Supplement (Impryl®) on Male Fertility","status":"ACTIVE_NOT_RECRUITING","sponsor":"Radboud University Medical Center","startDate":"2018-04-23","conditions":["Male Subfertility"],"enrollment":1200,"completionDate":"2026-04-30"},{"nctId":"NCT06841458","phase":"NA","title":"Six-Month Single-Blind, Placebo-Controlled Study of a Dietary Supplement Supplement on Hair Growth in 45 Volunteers","status":"RECRUITING","sponsor":"Industrial Farmacéutica Cantabria, S.A.","startDate":"2024-10-07","conditions":["Androgenetic Alopecia"],"enrollment":45,"completionDate":"2025-06-01"},{"nctId":"NCT01744782","phase":"PHASE3","title":"Safety/Effectiveness Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Cysteamine Treatment Naive Patients With Cystinosis","status":"COMPLETED","sponsor":"Amgen","startDate":"2012-12-20","conditions":["Cystinosis"],"enrollment":17,"completionDate":"2016-12-13"},{"nctId":"NCT05311085","phase":"PHASE3","title":"Cytisine and E-cigarettes With Supportive Text-messaging for Smoking Cessation (Cess@Tion)","status":"COMPLETED","sponsor":"University of Auckland, New Zealand","startDate":"2022-05-05","conditions":["Smoking Cessation"],"enrollment":807,"completionDate":"2024-07-26"},{"nctId":"NCT04126135","phase":"PHASE4","title":"Comparative Effectiveness of Cystine Versus Nicotine Replacement Therapy","status":"COMPLETED","sponsor":"Loma Linda University","startDate":"2022-01-27","conditions":["Nicotine Addiction"],"enrollment":1307,"completionDate":"2024-04-20"},{"nctId":"NCT06343272","phase":"NA","title":"Lymphocyte Enhancement in Gastroenteric Oncology","status":"RECRUITING","sponsor":"Fondazione IRCCS Policlinico San Matteo di Pavia","startDate":"2022-03-22","conditions":["Advanced Gastrointestinal Cancers"],"enrollment":54,"completionDate":"2025-02-28"},{"nctId":"NCT06298292","phase":"","title":"Acceptability/Tolerance of Protein Substitutes in Tablet Form for the Dietary Management of Rare Aminoacidopathies","status":"NOT_YET_RECRUITING","sponsor":"metaX Institut fuer Diatetik GmbH","startDate":"2024-04-01","conditions":["Tyrosinemia, Type I","Tyrosinemia, Type II","Tyrosinemia, Type III","Alkaptonuria","Homocystine; Metabolic Disorder","MSUD (Maple Syrup Urine Disease)"],"enrollment":15,"completionDate":"2026-06-30"},{"nctId":"NCT02910531","phase":"PHASE2","title":"Lipoic Acid Supplement for Cystine Stone","status":"ACTIVE_NOT_RECRUITING","sponsor":"Thomas Chi, MD","startDate":"2017-06-19","conditions":["Cystinuria"],"enrollment":50,"completionDate":"2025-06"},{"nctId":"NCT03663855","phase":"PHASE2","title":"Effect of Increasing Doses of Tiopronin on Cystine Capacity in Patients With Cystinuria","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2018-11-01","conditions":["Cystinuria"],"enrollment":10,"completionDate":"2019-09-10"},{"nctId":"NCT02125721","phase":"PHASE4","title":"Effect of Increasing Doses of Cystine Binding Thiol Drugs on Cystine Capacity in Patients With Cystinuria","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2012-06","conditions":["Cystinuria"],"enrollment":10,"completionDate":"2017-12"},{"nctId":"NCT03420976","phase":"EARLY_PHASE1","title":"Novel Supplement-based Therapy for the Treatment of Small Intestinal Bacterial Overgrowth","status":"WITHDRAWN","sponsor":"Atrium Innovations","startDate":"2017-12-07","conditions":["Small Intestinal Bacterial Overgrowth"],"enrollment":0,"completionDate":"2019-02-01"},{"nctId":"NCT02538016","phase":"NA","title":"TCUPS- Tolvaptan Use in Cystinuria and Urolithiasis: A Pilot Study","status":"COMPLETED","sponsor":"Caleb Nelson","startDate":"2016-10","conditions":["Cystinuria"],"enrollment":4,"completionDate":"2018-12"},{"nctId":"NCT02120105","phase":"","title":"Cystine Capacity Clinical Study (CysCap)","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2012-09","conditions":["Cystinuria"],"enrollment":30,"completionDate":"2017-02-24"},{"nctId":"NCT02499029","phase":"PHASE2","title":"N-acetylcysteine in the Treatment of PTSD and Addiction","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2013-02","conditions":["PTSD","Addiction"],"enrollment":35,"completionDate":"2014-09"},{"nctId":"NCT03364101","phase":"NA","title":"The Poweroff Sleep Study","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2017-10-01","conditions":["Sleep"],"enrollment":60,"completionDate":"2018-04-24"},{"nctId":"NCT03241472","phase":"PHASE3","title":"Induction of Ovulation Using Clomiphene Citrate and N-acetyl Cysteine Versus Letrozole","status":"COMPLETED","sponsor":"Assiut University","startDate":"2016-02","conditions":["Infertility"],"enrollment":100,"completionDate":"2017-06"},{"nctId":"NCT00071903","phase":"","title":"The Role of Susceptibility to Thrombosis in the Pseudotumor Cerebri of Nephropathic Cystinosis: A Case-Control Study","status":"COMPLETED","sponsor":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","startDate":"2003-10-30","conditions":["Pseudotumor Cerebri","Cystinosis"],"enrollment":18,"completionDate":"2008-07-18"},{"nctId":"NCT02942420","phase":"PHASE2","title":"Bucillamine Phase 2 Trial in Patients With Cystinuria","status":"UNKNOWN","sponsor":"Revive Therapeutics, Ltd.","startDate":"2017-05-01","conditions":["Cystinuria"],"enrollment":30,"completionDate":"2018-03"},{"nctId":"NCT01366859","phase":"PHASE2","title":"Nutritional Intervention in Children With Autism Using Whey Protein (Immunocal): Impact on Core Areas of Behavior","status":"COMPLETED","sponsor":"Nova Southeastern University","startDate":"2011-05","conditions":["Autism Spectrum Disorders"],"enrollment":81,"completionDate":"2016-10"},{"nctId":"NCT02766855","phase":"NA","title":"Efficacy of Topical Cysteamine in Nephropathic Cyctinosis","status":"COMPLETED","sponsor":"The Eye Center and The Eye Foundation for Research in Ophthalmology","startDate":"2004-01","conditions":["Nephropathic Cyctinosis","Corneal Cystine Crystals"],"enrollment":26,"completionDate":"2016-03"},{"nctId":"NCT00010426","phase":"NA","title":"Randomized Study of New Formulation Ophthalmic Cysteamine Hydrochloride for Corneal Cystine Accumulation in Patients With Cystinosis","status":"COMPLETED","sponsor":"FDA Office of Orphan Products Development","startDate":"1999-12","conditions":["Cystinosis"],"enrollment":30,"completionDate":"2001-02"},{"nctId":"NCT00001213","phase":"PHASE2","title":"Cysteamine Eye Drops to Treat Corneal Crystals in Cystinosis","status":"COMPLETED","sponsor":"National Eye Institute (NEI)","startDate":"1986-04","conditions":["Cystinosis"],"enrollment":328,"completionDate":"2013-07"},{"nctId":"NCT01327807","phase":"","title":"Cure Cystinosis International Registry","status":"UNKNOWN","sponsor":"Cystinosis Research Foundation","startDate":"2010-08","conditions":["Cystinosis","Nephropathic Cystinosis","Renal Fanconi Syndrome"],"enrollment":750,"completionDate":"2022-12"},{"nctId":"NCT00001736","phase":"PHASE1","title":"New Cysteamine Eye Drops Formulation to Treat Corneal Crystals in Cystinosis","status":"COMPLETED","sponsor":"National Eye Institute (NEI)","startDate":"1998-05","conditions":["Cystinosis"],"enrollment":51,"completionDate":"2001-03"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Sublingual"},"crossReferences":{"NUI":"N0000147293","MMSL":"4525","NDDF":"005113","UNII":"48TCX9A1VT","VUID":"4019019","CHEBI":"CHEBI:17376","VANDF":"4019019","INN_ID":"7922","RXNORM":"3036","UMLSCUI":"C0010682","chemblId":"CHEMBL590540","ChEMBL_ID":"CHEMBL590540","KEGG_DRUG":"D03636","DRUGBANK_ID":"DB00138","PDB_CHEM_ID":" IYY","PUBCHEM_CID":"67678","SNOMEDCT_US":"37927000","IUPHAR_LIGAND_ID":"5413","MESH_DESCRIPTOR_UI":"D003553"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":12263,"therapeuticAreas":["Other"],"biosimilarFilings":[],"recentPublications":[{"date":"2026 Mar 13","pmid":"41897515","title":"The Role of Ferroptosis in Diabetes Pathogenesis: Therapeutic Implications of Hydrogen Sulfide and Its Reactive Metabolites.","journal":"Antioxidants (Basel, Switzerland)"},{"date":"2026 Mar 26","pmid":"41894394","title":"Methionine metabolism is linked with phospholipid and glutamine metabolism to drive ferroptosis.","journal":"Cell reports"},{"date":"2026 Feb 26","pmid":"41892951","title":"Crude Venom from Sea Anemone Macrodactyla doreensis Suppresses Glioblastoma via the p53 Pathway.","journal":"Marine drugs"},{"date":"2026 Mar 20","pmid":"41889857","title":"Discovery of metabolites produced by reactions between central carbon metabolites and cysteine that mark inflammatory macrophages.","journal":"bioRxiv : the preprint server for biology"},{"date":"2026 Mar 25","pmid":"41879427","title":"Dimethyl fumarate combined with cisplatin at subcytotoxic doses sensitizes cervical cancer toward ferroptosis and apoptosis through GSH restriction and p53 (re)activation.","journal":"Molecular oncology"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:35:43.845465+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}